RT Journal Article SR Electronic T1 Lymphokine-activated Killer Cell Therapy Combined with High-dose Glucocorticoid Showed Clinical Efficacy towards Advanced Lung Carcinoma JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 3125 OP 3128 VO 30 IS 8 A1 MIKIO KATO A1 SHIGENORI GOTO A1 GEN-ICHIRO SOMA YR 2010 UL http://ar.iiarjournals.org/content/30/8/3125.abstract AB We describe the case of a patient with terminal adenocarcinoma of the lung with no response to lymphokine-activated killer (LAK) cell therapy alone who distinctly responded clinically to a combination of high-dose glucocorticoids (GC) and LAK cell therapy, administered by chance. However, after decreasing the dose of GC because of gastrointestinal bleeding caused by the high-dose treatment, there was no response on restarting GC plus LAK cell therapy. The clinical course of this case strongly suggests that local inflammation in the vicinity of tumors should be adequately suppressed in patients with advanced cancer who receive immunotherapy.